Nodenza Venture Partners, a New York-based venture capital firm focused on breakthrough life sciences technologies has announced its investment in Faction Imaging Inc. Completed in Dec 2024, the financing allowed Faction Imaging to meet a 10 million USD financing milestone, with Nodenza as lead VC. Faction is pioneering AI-native imaging technologies designed for future healthcare systems.
Medical imaging is foundational to clinical decision-making, yet current systems are under growing strain. Radiologists face unsustainable workloads, patients encounter delays, and legacy infrastructure is struggling to keep up with rising global demand.
Faction Imaging is developing a purpose-built platform to address these deep inefficiencies at the infrastructure level, combining custom AI-native hardware, advanced materials, and next-generation computational techniques. The goal is to deliver transformative gains in efficiency, accuracy, and scalability across imaging workflows.
“Faction is rethinking imaging from first principles, it’s the kind of leap healthcare systems urgently need. Their approach tackles deep structural problems that legacy technologies simply weren’t built to solve. We’re proud to back a team with the vision and capability to redefine this space,” said Ross Morton, Managing Partner at Nodenza Venture Partners.
Faction’s platform is not just designed to improve imaging quality, it aims to redefine the role of imaging in a modern, responsive healthcare system increasingly reliant on real-time diagnostics.
Matt McGrath, CEO and co-founder of Faction Imaging, added: “We’re thrilled to be working with Nodenza as we enter this next chapter. We’ve spent years in clinical environments around the world, from India to Japan to the U.S. studying workflows and bottlenecks. That insight, combined with focused technology development, puts us in a strong position to deliver meaningful change at global scale.”
After operating in stealth mode for several years, Faction Imaging says it has built a strong foundation of scientific innovation, with a differentiated IP portfolio and early prototype systems in development. The leadership team previously created and scaled a new medical visualisation segment now standard in tens of thousands of health systems and used by tens of millions of patients globally.
